GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
Confirmation of the good safety and tolerability profile of GS010
Improvement of visual acuity in patients with an onset of disease
of less than 2 years
Paris, 8 June 2016 – GenSight Biologics, a biotechnology company discovering and developing novel
gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system,
announces additional promising results of its Phase I/II study, designed to demonstrate the safety and
tolerability of GS010 in 15 patients with Leber’s Hereditary Optic Neuropathy (LHON).
Each cohort of three patients was administered an escalating dose of GS010 through a single intravitreal
injection in the eye most severely affected by the disease. Recruitment was completed in April 2015.
These patients had an average onset of disease of 6 years.
At 48 weeks post-injection, in patients with an onset of disease of less than 2 years, a gain of +30 letters
(-0.59 LogMAR) was observed in the treated eye and +13 letters (-0.25 LogMAR) in the untreated eye, a
difference of 17 letters in favor of the treated eye. No significant difference was observed in patients with
an onset of disease of more than two years.
Note (*): Excludes hand motion patients (hand movements between 30cm and 1m), in accordance with the Phase III protocol
The combined effect of the administered dose and the time from onset is noticeable at 36 weeks and
stable after 48 weeks.
Evolution of visual acuity in the treated eye vs. untreated eye
(in equivalent number of letters read)
Bernard Gilly, CEO and co-founder of GenSight, commented: “This preliminary data is very encouraging
and validates the design of the two Phase III studies currently ongoing in the US and Europe on GS010
for the treatment of Leber’s Hereditary Optic Neuropathy, a neurodegenerative retinal disease, and more
specifically of the optic nerve. Moreover, these results support the potential of our mitochondrial targeting
sequence technology platform or MTS, and allows us to envision other applications in diseases involving
defects of the mitochondrion, in ophthalmology as well as in other therapeutic areas.”
GS010 targets LHON, a rare maternally inherited mitochondrial genetic disease, characterized by the
degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal
blindness, and mainly affects adolescents and young adults. GS010 leverages a mitochondrial targeting
sequence (MTS) proprietary technology platform, arising from research works conducted at the Institut
de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically
address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of
interest is transferred into the cell to be expressed and produce the functional protein, which will then be
shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or
deficient mitochondrial function.
Dr. Catherine Vignal, investigator of the study and Head of Department of Ophthalmology at the
Rothschild Foundation Hospital in Paris, added: “These preliminary data at 48 weeks give significant hope
to patients suffering from LHON, a very severe disease with no existing curative treatment.”
Gensight Biologics is currently conducting two Phase III clinical studies (Rescue and Reverse) in
Europe and the United States to assess the efficacy of GS010 in patients affected with LHON due
to the ND4 mutation, with an onset of vision loss of less than one year. The top-line results at 48
weeks follow-up are expected in late 2017.
Chief Financial Officer
+33 (0) 6 01 36 35 43
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for
neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline
leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics, to help
preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead
product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial
disease that leads to irreversible vision loss in teens and young adults. Using its gene therapy-based approach,
GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by
intravitreal injection in order to offer patients a sustainable functional visual recovery.